Dr. Wang is an Assistant Professor in the Life Sciences Institute and Department of Chemistry at the University of Michigan. Dr. Lucas Cheadle is an assistant professor of neuroscience at Cold Spring Harbor Laboratory on Long Island, New York. The Hayward, California-based biotechnology company also raised $106 million in the first close of a Series C round, bringing the companys total funding to nearly $775 million since its public debut two years ago. Emily Goldberg is an Assistant Professor in the Department of Physiology at UCSF where her lab studies how coordination between immune and metabolic systems controls inflammation and chronic disease. Her research focuses on expansion and development of targeted protein degradation and proximity-mediated pharmacology strategies, and applying them to interrogate disease biology and develop new therapeutics. Dr. Sen's work has been recognized with a NextGen Star Award from the American Association of Cancer Research (AACR), a Young Investigator Award from the Melanoma Research Alliance, and a V Foundation Scholar Award. Eikon did just that, today announcing a monster Series B round of $517.8 million that the company plans to apply toward its high-resolution protein microscopy, He received his B.Sc. Project Title: Unraveling the Developmental Logic of Cortical Long-Range Projections Using In Situ Sequencing-Based Neuroanatomy She is also the founder of Leading Edge, an initiative to improve the gender diversity of faculty in the biomedical sciences. and M.S. His research activities span across several fields, including novel micro-/nano-fabrication, nanophotonics and metasurface, molecular fluidic dynamics, nanopore sensing, and biomarker detection. By: Eikon Therapeutics, Inc. via Business Wire. Funded by the Fulbright Fellowship, in 2010 she moved to the US and completed her Ph.D. at Stony Brook University, where she discovered the oncogenic roles and prognostic value of keratin 17 under the mentorship of Dr. Ken Shroyer. Under the collaboration agreement, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan). Project Title: The Inactive X: Discovering Sex Genes that Influence Female Vulnerability to Alzheimer's Disease He completed his Ph.D in Biochemistry at the University of Western Ontario (Canada) and then completed his postdoctoral studies at Massachusetts General Hospital and Harvard Medical School. Before becoming faculty, he studied mathematics (B.S. Healthcare Venture Investment Q1 2022 | Silicon Valley Bank our sites and services. Grant ID: DP2-GM150018 Eikon Therapeutics Stock Price, Funding, Valuation, Revenue At the Allen Institute, Xiaoyin's team is focusing on further developing in situ sequencing-based neuroanatomical techniques and applying them to understand the development and evolution of brain circuits. 'How can you understand life if you don't look at it live?' Grant ID: DP2-CA281401. The Column Group invested in Eikon Therapeutics's Series B funding round. Project Title: Understanding Metabolism in Space and Time Mechanistic Analysis of the Dynamic Spatial Organization of Metabolism Eikon hasnt provided details. Grant ID: DP2-HL168563. Project Title: New classes of optogenetic and chemogenetic tools with a feedback control Grant ID: DP2-GM149551 Her work has been supported by a K23 Mentored Patient-Oriented Research Career Development Award from the National Heart, Lung, and Blood Institute. A Phylodynamic Time Machine for Solid Tumors, Chemical Control of Misfolded Protein Fate. Grant ID: DP2-NS131566. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Eikon, which previously hadnt disclosed anything about its pipeline, has also begun acquiring assets. Perlmutter helped Merck establish KEYTRUDA as a foundational immunotherapy for cancer care. For her postdoctoral studies, Dr. Escolano joined the laboratory of Dr. Michel Nussenzweig at The Rockefeller University, where she worked on the development of novel sequential immunization strategies against HIV-1, studies that were recognized as one of the Notable Scientific Advances of 2016 by Nature Medicine. She obtained her PhD at University of California San Francisco, in the lab of Jonathan Weissman, where she pioneered a high-throughput approach to measure RNA structure in cells. WebTotal Funding $665.8 M Company summary Overview Eikon Therapeutics is a biopharmaceutical company that provides a method of drug discovery based on tracking and measuring the movement of individual proteins in live cells. Eikon Therapeutics, which develops applications to apply live-cell super-resolution microscopy to drug discovery, announced in January that it raised $518 million in Series B financing. CEO Roger Heerman Eikon Therapeutics Executive Team & Key Decision Makers Show Me More Executives Recently Updated Team Members Show Me More Team Members Top Eikon Therapeutics Integrations and Technologies Steven E. Mansoor is a physician-scientist in the Department of Chemical Physiology and Biochemistry (CPB) and the Knight Cardiovascular Institute (KCVI) at Oregon Health & Science University (OHSU). The AI systems he is developing can enable real-time, closed loop control which predicts future intent of human operators to adapt to changes in human and environmental state to improve community ambulation capability. Project Title: Deciphering Principles of Human Embryonic Patterning in Development and Disease Funded by the National Institute of General Medical Sciences. John James Blazeck, Ph.D. Georgia Institute of Technology. Grant ID: DP2-GM150192 Dr. Niepa is an Assistant Professor of Chemical and Petroleum Engineering at the University of Pittsburgh. Grant ID: DP2-CA280623. BD selected this specific site in Ward 4 because it sits within compatible existing and planned industrial areas. She then completed her postdoctoral work at Memorial Sloan Kettering Cancer Center under the mentorship of Drs. Its funding strategy is a sign of the times for startups. WebContact Who is Eikon Therapeutics Headquarters 3929 Point Eden Way, Hayward, California, 94545, United States Phone Number (415) 865-2050 Website www.eikontx.com Revenue $15.2M Industry Drug Manufacturing & Research Pharmaceuticals Healthcare Eikon Therapeutics's Social Media Is this data correct? Project Title: Determining Age-Dependent Metabolic Changes in Tumors and Their Microenvironment ", Joe Snell, president & CEO, Sun Corridor Inc., said, "We were tenacious in our efforts to win this project. Prior to joining ASU, he obtained his Ph.D. degree in Jan 2012 from department of Electrical Engineering at Princeton University, and worked as a postdoctoral research scientist at IBM T.J. Watson research center until 2015. From 2016-2019, Maral was a postdoctoral fellow in the research group of Prof. George Whitesides at Harvard University, and Wyss Institute for Biologically Inspired Engineering, working on affordable diagnostic devices to make healthcare and analysis accessible to all. Eikon Steven Leach and Omar Abdel-Wahab, where she identified altered RNA splicing as the mechanism of cooperation between mutant p53 and KRAS, two of the most common co-occurring mutations in cancer. You couldnt see them as they were working. Grant ID: DP2-MH132940. IMP1734 is a novel and highly PARP1 selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Prior to receiving the NIH Directors New Innovator Award, Steven has received an NIH Pathway to Independence Award (K99/R00) from the National Heart, Lung, and Blood Institute (NHLBI), an American Society for Clinical Investigation (ASCI) Young Physician-Scientist Award, and a Gilead Research Scholars Award in Cardiovascular Comorbidities. Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the purposeful integration of engineering The Smeeton lab aims to uncover the cellular and molecular mechanisms driving the development and regeneration of synovial joint tissues, including ligaments and articular cartilage. Its pipeline will continue to grow both organically and through strategic partnerships, largely asset acquisitions, he said. Xiaoyin is an Assistant Investigator at Allen Institute for Brain Science. As a Helen Hay Whitney Postdoctoral Fellow in Karel Svoboda lab at Janelia Research Campus, HHMI, he studied the neuronal mechanisms of short-term memory in mice. 2013) at UCLA, and bioengineering as a postdoctoral fellow at Stanford University. His research efforts focus on expanding our understanding of cellular behavior through technological innovation in single cell genomics. Grant ID: DP2-OD032793. As a postdoctoral fellow with Dr. Alexander Schier, she studied the genes involved in complex neuropsychiatric disorders, generating over a hundred zebrafish mutants for schizophrenia-associated genes and assessing their brain activity, brain structure, and behavior. SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ --IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Eikon Therapeutics ("Eikon"), a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and sciencetoday announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023. This is a BETA experience. Eikon is now following with a round that values the company at a meaningful step-up to a nearly $518 million Series B and includes several new strategic investors, Perlmutter said. Eikon expects to complete the He received his M.D. Lindsay Case is currently an Assistant Professor in the Department of Biology at MIT, where her lab studies how cells regulate the spatial organization of signaling molecules at the plasma membrane. Dr. Risca is a recipient of the V Scholar Award and a Rita Allen Scholar Award. In addition to the New Innovator Award, Dr. Arey has received support from the Caroline Wiess Law Fund for Research in Molecular Medicine, the Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty, and the Whitehall Foundation. (Hons. In addition to the NIH Director's New Innovator, Dr. Niepa received numerous awards, including an S-STEM grant and the 2022 CAREER Award from the National Science Foundation to promote diversity in engineering research and education. Grant ID: DP2-AI175641. Dr. Aaron Whiteley is an Assistant Professor in the Department of Biochemistry at the University of Colorado Boulder. Investors for this round include funds and accounts managed by T. Rowe Price, Soros Capital, General Catalyst, E15 VC, Hartford Healthcare Endowment, AME Cloud Ventures, UC Investments, CPP Investments, Schroeders Capital, Harel Insurance and StepStone Group. Uhler develops machine learning methods for integrating and translating between vastly different data modalities and inferring causal or regulatory relationships from such data. Len Pennacchio and Axel Visel at Berkeley lab, where he investigated the molecular basis of vertebrate evolution and human congenital disorders. Perlmutter was previously an executive vice president at Merck and president of Merck Research Laboratories. He earned a Ph.D. in Biochemistry from Max Planck Institute of Molecular Physiology/TU Dortmund working in Stefan Raunsers laboratory. So far this year, at least 46 biotechs have raised rounds of $100 million or more, per Crunchbase data. Her field of expertise is in the investigation of sex differences in Alzheimer's disease (AD) biomarkers in preclinical AD; specifically, her interests lie in what sex biological mechanisms might explain female vulnerability, and resilience, to AD pathology and subsequent cognitive decline. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Funded by the National Institute of General Medical Sciences. Under his leadership, Merck received more than 100 regulatory approvals for its medicines and vaccines globally, including those for multiple cancers, diabetes, and infectious diseases. Most recently, the Goldberg lab has become interested in the aging tissue-resident immune system and how this contributes to functional decline. Project partners include the Arizona Commerce Authority, City of Tucson, Pima County, Pima Community College, Tucson Electric Power, Southwest Gas, Lumen, Primus Builders, Perry Engineering, Azbil Telstar, Lesni A/S, Advanced Air Technologies, Inc, Cushman & Wakefield/PICOR and JLL (Jones Lang LaSalle). Grant ID: DP2-DK136278. This facility will be one of the first in the world with an original design that will meet or exceed the most stringent environmental guidelines and serve as a model for other sites worldwide. Funded by the National Institute of General Medical Sciences. How Eikon Uses Fluorescence Microscopy for Drug Discovery He received his B.Sc. in Computer Science and Microbiology at the University of British Columbia. In addition to the NIH Directors New Innovator Award, Joanna is also a recipient of the NIH Pathway to Independence Award. Project Title: Causal Representation Learning for the Spatial Analysis of Transcriptomic and Imaging Data in Tissue Contexts While in the Baltimore lab, he began working on cell engineering using chimeric receptors and created a cell-based T cell epitope discovery method. News Jan 6, 2022 swfinstitute.org Public Funds Join in Eikon Therapeutics Series B Round News Jan 6, 2022 BioSpace Eikon Boasts Stellar Leadership Lineup and Massive $518 Million Series B News Jan 6, 2022 Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive In addition to the NIH Directors New Innovator Award, Zheng is a recipient of the NIH K99/R00 Pathway to Independence Award and the Charles E. Kaufman Foundation New Investigator Award. As a graduate student at Emory University, Chris investigated the contributions of voltage-gated sodium channels to the development of epilepsy in the laboratory of Dr. Andrew Escayg. TUCSON, Ariz., April 1, 2021 /PRNewswire/ --BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company's supply chain, serving as a final-stage manufacturing and sterilization center. For many of these individuals with neurological injury or limb loss, mobility throughout the local community is greatly impaired-- a phenomenon which has implications on long term health, economics (such as the ability to work a job), independence and quality of life. Marals research experiences and interests span from point-of-care diagnostics, to electrochemical sensors, wearable devices, neural probes, and tools for precision medicine. in Biomedical Sciences. She received her B.S. Project Title: Universally-applicable RNA mapping at subcellular and single-base resolution Funded by the National Institute of General Medical Sciences. Dr. Grubaugh is currently an Associate Professor in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health. There were 20 financings over $100M in Q1: Altos Labs ($3B) Eikon ($518M) Kallyope ($236M) Maze ($190M) We also noted a significant decrease in the number of deals from 2021, including Series A. He received a Ph.D. in Medical and Electrical Engineering from MIT in 2012, where he performed bioprinting research with Dr. M. Fatih Yanik. About BD You can read more about your cookie choices at our privacy policyhere. BD operates more than 90 medical device and health care technology manufacturing and sterilization facilities globally and has a track record of sustainable operations. Dr. Delaney performed his post-doctoral cancer biology and DNA repair research at the University of California at San Diego and Duke University under the mentorship of Dr. Dwayne Stupack and Dr. Albert La Spada. Along with Baynes, its leadership team includes former Merck executive Ben Thorner and its board includes ex-CEO Ken Frazier. He went on to perform his Ph.D. work with Dr. Jen Liou at UT Southwestern Medical Center, where he developed synthetic markers to study how lipid and Ca2+ signaling is relayed between organelles. Dr. Cheadles work merges cutting-edge approaches ranging from in vivo multi-photon microscopy to single-cell genomics to define the contributions of the immune system to brain development and function. Dr. Ponces research program is aimed at discovering and characterizing the visual representations of the primate brain, using machine intelligence approaches. Originally from Canada, she earned her B.Sc. With the support of our investors, we continue to make dramatic progress in the industrialization of our live-cell imaging platform. She began her lab in January 2020. in Bioinformatics from Saarland University. Vikram is a recipient of the Searle Scholar Award, the Peter and Patricia Gruber International Research Award in Neuroscience, the NIH K99/R00 Pathway to Independence Award, and the Simons Collaboration on the Global Brain Postdoctoral Fellowship. Her graduate work centered on epigenetic regulation during mammalian embryogenesis and she received her Ph.D. in Computational and Systems Biology from M.I.T. Startup Eikon, led by Merck vets, buys three drugs and banks Eikon Therapeutics is a drug discovery and development company working to advance breakthrough therapeutics through the Grant ID: DP2-GM150017 in physics from Stanford university and a Ph.D. in biophysics from the University of California, Berkeley, where she studied how mechanical forces regulate nucleation in branched actin networks in the laboratory of Dr. Daniel Fletcher. Weve developed new technology that allowed us to do things that were not possible before.. Luisa Escobar-Hoyos is an Assistant Professor in the Departments of Therapeutic Radiology and Molecular Biophysics and Biochemistry at Yale University. As a Ph.D. student with Dr. David Baker, she engineered biomolecular interactions, providing the foundation and skills for her long-term goals of developing new therapeutics for these disorders. Conroy continued, "Tucson's economic transformation is a national success story, and BD is excited to be part of it.
Adopt A Family For Christmas Ventura County,
Petal Fresh Shampoo Anti Dandruff,
Anglo-eastern Maritime Address,
Yale Linus Compatibility,
Condos For Sale San Francisco,
Articles E